JPRN-UMIN000029306招募中未知
Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer - Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer
niversity of the Ryukyus0 个研究点目标入组 63 人开始时间: 2017年9月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients whose pathologically confirmed para aortic lymph node (PAN) metastasis. Patients who are suspected of PAN metastasis by preoperative imaging (CT with a short diameter of 10mm or more, suspicious metastasis with PET/CT, can't be registered if pathological negative is not confirmed. 2. Patients with active double cancer (synchronous double cancer and metachronous double cancer with disease-free period within 5 years). 3. Patient who have been treated with anti-VEGF and anti-VEGFR formulations. 4. Patients with symptomatic cerebrovascular disorders. 5. Patients with a high probability of bleeding due to congenital hemorrhagic diathesis, abnormal coagulation, etc. 6. Patients with severe cardiovascular disorders (such as poor control hypertension). 7. Patients with clinical symptoms of intestinal obstruction. 8. Patients with infection requiring systemic administration such as antibiotics, antivirals, antifungal drugs at registration. 9. Patients who received radiotherapy or chemotherapy before surgery.
研究者
相似试验
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapymetastatic colorectal cancerJPRN-UMIN000002407Sapporo City General Hospital20
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE
已完成
不适用
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25